Results 111 to 120 of about 54,905 (262)

Pregnancy in primary biliary cirrhosis

open access: bronze, 1992
Kok-Kien Wong, Khean‐Lee Goh
openalex   +1 more source

Interventional oncology in children: Where are we now?

open access: yesJournal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel   +1 more
wiley   +1 more source

Imaging of Abdominal Complications in Children With Acute Lymphoblastic Leukaemia

open access: yesJournal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and remains one of the most common causes of cancer‐related death in children and adolescents. Five‐year overall survival rates now exceed 90% with current multidrug chemotherapeutic regimens. This improvement, coupled with the toxicity of chemotherapy, has led to the
Luke R. Holmes   +2 more
wiley   +1 more source

Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
This study evaluated the performance of the PAGE‐B score in HCC risk among CHB patients with metabolic dysfunction or MASLD. The PAGE‐B score effectively stratified HCC risk in both MASLD and non‐MASLD patients, especially in those without cirrhosis, where low scores were linked to negligible 5‐year HCC risk. ABSTRACT Introduction Metabolic dysfunction
Lesley A. Patmore   +22 more
wiley   +1 more source

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy